The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.

Abstract

We discussed the role of DNA topoisomerase I (topo I) inhibitor, which is now widely used in clinical practice, in cisplatin-resistant ovarian cancer. Our study showed the synergistic actions between cisplatin and 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of 7-ethyl-10-[4-(1-pyperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11), in… (More)

Topics

Cite this paper

@article{Minagawa2001TheRO, title={The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.}, author={Yasuyo Minagawa and Junzo Kigawa and Hiroaki Itamochi and Nobue Terakawa}, journal={Human cell}, year={2001}, volume={14 3}, pages={237-43} }